Renal Cancer

Renal Cancer
2022-03-06T00:00:00.000+00:00
Ongoing

SAMETA

SAMETA
Renal cancer

A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma

A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA)

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Renal cancer

Study Phase

III

Trial Identifiers

Registration number: NCT05043090

https://clinicaltrials.gov/study/NCT05043090

GenesisCare Location(s)
North Shore
location pin icon

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

phone icon (02) 8037 4100 email icon admin.northshore@genesiscare.com
NSW
North Shore
Principal Investigator(s)
Medical Oncologist

Dr Laurence Krieger

MBChB (Hons) FRACP

Dr Laurence Krieger
location pin icon

North Shore

View Profile
Profile Image - Dr Laurence Krieger

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.